Scinovex
reviewTop 1% cited

Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways

Immunological Reviews · 2008 · Vol. 224(1) · pp. 166–182
Brian T. FifeJeffrey A. Bluestone

Abstract

Classically, the CD28/cytotoxic T-lymphocyte antigen-4 (CTLA-4) and B7 families of cell surface molecules regulate complex signaling pathways that profoundly affect T-cell responses. The recent identification and characterization of additional CD28 and B7 family members including programmed death-1 (PD-1), programmed death ligand-1 (PD-L1) (B7-H1), and PD-L2 (B7-DC) has added to the complexity and greater appreciation of how surface molecules control T-cell activation and peripheral tolerance. CD28/B7 interactions mediate co-stimulation and significantly enhance peripheral T-cell responses. CTLA-4, in contrast, interacting with the same B7 molecules, results in decreased T-lymphocyte activity and regulates the immune response. Similarly, PD-1 interactions with PD-L1 and PD-L2 downmodulate T-cell immune responses. Despite these similarities, the regulatory roles of the CTLA-4 and PD-1 pathways are distinct. This may be due, at least in part, to the differential expression patterns of the CTLA-4 and PD-1 ligands both temporally and spatially. This article examines the role of CTLA-4 and PD-1 in limiting autoreactivity and establishing peripheral self-tolerance with the hypothesis that CTLA-4 signals are required early in the lymph node during initiation of an immune response and PD-1 pathways act late at the tissue sites to limit T-cell activity.

Immune Cell Function and InteractionT-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersPeripheral toleranceCD28BiologyT cellCytotoxic T cellCTLA-4Immune systemImmunologyImmune toleranceCell biology

MeSH terms

AbataceptAnimalsAntibodies, MonoclonalAutoimmune DiseasesHumansImmune ToleranceImmunotherapyLymphocyte ActivationT-LymphocytesSignal TransductionAutoimmunityAntigens, CDClonal AnergyImmunoconjugatesApoptosis Regulatory Proteins

Funding

  • National Institutes of Health
Citations
1,021
FWCI
14.28
field-weighted impact
References
144
Percentile
99%
vs. same field & year
Citations per year
Cited by
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Journal of Cellular Physiology · 2018 · 506 citations
PD‐1 signaling in primary T cells
Immunological Reviews · 2009 · 762 citations
Molecular mechanisms of T cell co-stimulation and co-inhibition
Nature reviews. Immunology · 2013 · 3,032 citations
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Nature reviews. Immunology · 2020 · 4,024 citations
Related articles
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
The Journal of Experimental Medicine · 1995 · 2,186 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.